TRANSMEDICA's Laser Lancet(R) Receives Broad FDA Clearance
LITTLE ROCK, Ark., July 14 /PRNewswire/ -- TRANSMEDICA International,
Inc.
announced today that its Laser Lancet(R) has received broad clearance
from the
U. S. Food and Drug Administration "for the perforation of skin to draw
capillary blood for screening purposes."
The Laser Lancet(R) is a small, portable, battery operated Er:YAG laser
that
eliminates the need for steel lancets, thereby ending the possibilities
of
accidental sticks and the attendant danger of transmission of blood
borne
pathogens.
"The elimination of the use of sharps in one of medicine's most common
procedures vastly improves the safety of every health care worker who
draws
capillary blood," said Charles H. Vestal, TRANSMEDICA's President and
Chief
Executive Officer. He added, "this is also great news for patients
because a
blood draw effected by the Laser Lancet(R) is virtually painless."
The clinical data submitted to the FDA demonstrated that the Laser
Lancet(R)
is both safe and efficacious. The data also proved that the healing rate
of
the skin perforation was equal to or better than perforations performed
with
potentially hazardous steel lancets. "More good news for patients," said
Vestal.
TRANSMEDICA's Laser Lancet(R) employs a one-time-use disposable plastic
tip
that does not demand the special disposal techniques required for
sharps, such
as steel lancets.
"We are extremely gratified to be able to make health care workers
safer, and
patients more comfortable," said Vestal, adding, "it's great news for
everyone."
The Laser Lancet(R) is manufactured for TRANSMEDICA by LaBarge, Inc.
(Amex:
LB), a St. Louis, MO firm that designs and manufactures high performance
electronics for a variety of industries.
More information about TRANSMEDICA International, Inc. may be found at
HYPERLINK "http://www.transmedicainc.com/" or by calling J. Craig
Barnes, Vice
President of Communications for TRANSMEDICA International, Inc.,
501-376-3938,
National Pager, 888-992-5305, or Mailto: cbarnes@transmedicainc.com.
SOURCE TRANSMEDICA International, Inc.
CO: TRANSMEDICA International, Inc.; LaBarge, Inc.
ST: Arkansas, Missouri
IN: MTC CPR
SU:
God Bless
marty auslander
------------------------------
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
